ArticleEsophagus : official journal of the Japan Esophageal Society2026
Bidirectional risk of autoimmune disease and eosinophilic esophagitis in Sweden.
Article in Esophagus : official journal of the Japan Esophageal Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundEosinophilic esophagitis (EoE) shares several risk factors with other autoimmune diseases, but population-based studies in this field are limited.
methodsUsing the Swedish nationwide histopathology cohort Epidemiology Strengthened by histopathology Reports in Sweden (ESPRESSO), we identified all patients in Sweden with EoE and matched them by age, sex, county of residence and calendar year with up to 5 general population reference individuals. Using Cox regression modelling, we calculated hazard ratios (HRs) for future autoimmune disease as recorded in the National Patient Register. Using conditional logistic regression, we also calculated odds ratios (ORs) for autoimmune disease prior to EoE.
resultsWe identified 1477 individuals with EoE and 6933 matched reference individuals from the general population. During a median follow-up of 8 years, 44 EoE patients (2.98%) and 113 reference individuals (1.63%) developed autoimmune disease with incidence rates of 3.54 and 1.93 per 1000 person-years, respectively. The adjusted HR for subsequent autoimmune disease was 1.83 (95% CI = 1.29-2.59) among patients with EoE compared to general population reference individuals. Excluding inflammatory bowel disease and celiac disease from our composite outcome, the adjusted HR for non-gastrointestinal autoimmunity was 1.45 (95% CI = 0.93-2.25). EoE was also associated with earlier autoimmune disease with 7.9% of EoE patients having a record of an autoimmune disease before EoE, as compared with 2.9% of reference individuals (OR = 2.92; 95% CI = 2.34-3.65).
conclusionEoE was associated with both antecedent and subsequent autoimmune disease, which was strongly driven by gastrointestinal autoimmune conditions. While associations with non-gastrointestinal autoimmune diseases did not reach statistical significance in the present analysis, they warrant further investigation. Clinicians treating patients with EoE should be aware of the increased risk of concomitant or future autoimmunity.
Indexed as
Identifiers
42165952What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.